Keep Your Eyes on Stock News: Stealth BioTherapeutics Corp (NASDAQ:MITO)

On Monday Stealth BioTherapeutics Corp (NASDAQ:MITO) traded with change of 4.95% on volume of 7690 shares in the last session as compared to average volume of 74743 shares. During last trade its minimum price was $6.5 and it gained highest price of $6.94. MITO has total market capitalization of $237876241. Its closing value stands at $6.79.

On Nov. 11, 2019, Stealth BioTherapeutics Corp (NASDAQ:MITO) a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, declared that it will report third quarter 2019 financial results On THursday, November 14, 2019, before the market opens.

About Stealth

We are a clinical-stage biotechnology company focused on improving the lives of patients suffering from diseases involving mitochondrial dysfunction through the discovery, development and commercialization of novel mitochondrial medicines. Mitochondria, found in nearly every cell in the body, are the body’s main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases, collectively known as primary mitochondrial diseases, and are also involved in many common age-related diseases. We believe our lead product candidate, elamipretide, has the potential to treat both rare genetic and common age-related mitochondrial diseases. We are studying elamipretide in the following primary mitochondrial diseases: primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy. We are also studying elamipretide in geographic atrophy associated with dry age-related macular degeneration. Our other pipeline candidates include SBT-272, which we are evaluating for rare neurodegenerative disease indications, and SBT-20 and SBT-259, being evaluated for rare peripheral neuropathies. We have optimized our discovery platform to identify novel mitochondrial-targeted compounds, which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria. We have assembled a highly experienced management team, board of directors and group of scientific advisors to help us achieve our mission of leading mitochondrial medicine.

Leave a Reply

Your email address will not be published. Required fields are marked *